Flare Therapeutics logo

Flare Therapeutics Funding & Investors

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

flaretx.com

Total Amount Raised: $205,000,000

Flare Therapeutics Funding Rounds

  • Series B

    $123,000,000

    Series B Investors

    Eventide
    Memorial Sloan Kettering Cancer Center
    Eli Lilly
    Pfizer Venture Investments
    Nextech Invest
    GordonMD Global Investments
    Pavilion Capital
    Novartis
    Agent Capital
    Invus Group
    Third Rock Ventures
    Shangbay Capital
    Casdin Capital
    Boxer Capital
  • Series A

    $82,000,000

    Series A Investors

    Eventide
    Invus Group
    Third Rock Ventures
    Nextech Invest
    Casdin Capital
    Boxer Capital
Funding info provided by Diffbot.